PICATO

This brand name is authorized in United States. It is also authorized in Brazil, Estonia, Lithuania, Poland, Romania.

Active ingredients

The drug PICATO contains one active pharmaceutical ingredient (API):

1	Ingenol mebutate UNII 7686S50JAH - INGENOL MEBUTATE
	Picato is indicated for the cutaneous treatment of non-hyperkeratotic, non-hypertrophic actinic keratosis in adults. The mechanism of action of ingenol mebutate for use in actinic keratosis remains to be fully characterised. Results from two clinical studies on biological effects of ingenol mebutate have shown that topical administration induced epidermal necrosis and a profound inflammatory response in both epidermis and the upper dermis of the treated skin, dominated by infiltrating T cells, neutrophils and macrophages.
	Read more about Ingenol mebutate

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
PICATO Gel	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
D06BX02		D Dermatologicals → D06 Antibiotics and chemotherapeutics for dermatological use → D06B Chemotherapeutics for topical use → D06BX Other chemotherapeutics
Discover more medicines within D06BX02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
BR	Câmara de Regulação do Mercado de Medicamentos	541112120001102
EE	Ravimiamet	1598698, 1598700
LT	Valstybinė vaistų kontrolės tarnyba	1068377, 1068378
PL	Rejestru Produktów Leczniczych	100295535, 100295630
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W59715001, W59716001
US	FDA, National Drug Code	50222-502, 50222-503